That is the one data point I am looking for: the eGFR change for patients with eGFR less than 60. 

If that is statistically significant and causes eGFR to go up a few % points like in the Phase 2 trial (3.4% increase in eGFR in Phase 2), then I will be satisfied that Apabetalone remains a Humira in the making.  And more positive that the Dementia outcome will go the right way.

It would still need some explaining why the eGFR for the general Apabetalone patient group did not change at all.  

While on the topic of discussing the medical data, it is worth mentioning that HDL went up 16% vs placebo at 10% and it was statistically very significant.  This proves that the original reverse cholesterol transport was working as expected...it would help to know what sized HDL went up for Apabetalone. 

But then there is a slightly odd result where HDL and LDL went up for all patients.  Of course, it was comforting that Apabetalone went in the right direction for both HDL and LDL...but still...why did LDL go up so much (11% and 15% respectively)?